Literature DB >> 18588888

Stathmin/Op18 is a novel mediator of vinblastine activity.

Francois Devred1, Philipp O Tsvetkov, Pascale Barbier, Diane Allegro, Susan Band Horwitz, Alexander A Makarov, Vincent Peyrot.   

Abstract

Microtubule (MT) dynamic instability is tightly regulated by stabilizing and destabilizing proteins, the latter being exemplified by stathmin/Op18, a protein known to destabilize MTs. Studies in cells have indicated that the level of stathmin expression modifies the cytotoxicity of antimicrotubule drugs, such as vinblastine (VLB). Using isothermal titration calorimetry and analytical ultracentrifugation, we show that VLB increases the affinity of stathmin for tubulin 50-fold (and vice versa). These results are the first biochemical evidence of the direct relationship between stathmin and an antimitotic drug, and reveal a new mechanism of action for VLB.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18588888      PMCID: PMC2837597          DOI: 10.1016/j.febslet.2008.06.035

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  25 in total

Review 1.  Physiochemical aspects of tubulin-interacting antimitotic drugs.

Authors:  J J Correia; S Lobert
Journal:  Curr Pharm Des       Date:  2001-09       Impact factor: 3.116

2.  DNA gyrase interaction with coumarin-based inhibitors: the role of the hydroxybenzoate isopentenyl moiety and the 5'-methyl group of the noviose.

Authors:  Daniel Lafitte; Valérie Lamour; Philippe O Tsvetkov; Alexander A Makarov; Michel Klich; Pierre Deprez; Dino Moras; Claudette Briand; Robert Gilli
Journal:  Biochemistry       Date:  2002-06-11       Impact factor: 3.162

3.  Stathmin family proteins display specific molecular and tubulin binding properties.

Authors:  E Charbaut; P A Curmi; S Ozon; S Lachkar; V Redeker; A Sobel
Journal:  J Biol Chem       Date:  2001-02-15       Impact factor: 5.157

4.  First tau repeat domain binding to growing and taxol-stabilized microtubules, and serine 262 residue phosphorylation.

Authors:  François Devred; Soazig Douillard; Claudette Briand; Vincent Peyrot
Journal:  FEBS Lett       Date:  2002-07-17       Impact factor: 4.124

5.  The phosphoprotein Op18/stathmin is differentially expressed in ovarian cancer.

Authors:  D K Price; J R Ball; Z Bahrani-Mostafavi; J C Vachris; J S Kaufman; R W Naumann; R V Higgins; J B Hall
Journal:  Cancer Invest       Date:  2000       Impact factor: 2.176

Review 6.  Tau protein isoforms, phosphorylation and role in neurodegenerative disorders.

Authors:  L Buée; T Bussière; V Buée-Scherrer; A Delacourte; P R Hof
Journal:  Brain Res Brain Res Rev       Date:  2000-08

7.  Thermodynamics of the Op18/stathmin-tubulin interaction.

Authors:  Srinivas Honnappa; Brian Cutting; Wolfgang Jahnke; Joachim Seelig; Michel O Steinmetz
Journal:  J Biol Chem       Date:  2003-07-14       Impact factor: 5.157

8.  Vinflunine, a novel microtubule inhibitor, suppresses calmodulin interaction with the microtubule-associated protein STOP.

Authors:  Alexander A Makarov; Philipp O Tsvetkov; Claude Villard; Didier Esquieu; Bertrand Pourroy; Jacques Fahy; Diane Braguer; Vincent Peyrot; Daniel Lafitte
Journal:  Biochemistry       Date:  2007-12-04       Impact factor: 3.162

9.  Overexpression of stathmin in breast carcinomas points out to highly proliferative tumours.

Authors:  P A Curmi; C Noguès; S Lachkar; N Carelle; M P Gonthier; A Sobel; R Lidereau; I Bièche
Journal:  Br J Cancer       Date:  2000-01       Impact factor: 7.640

10.  Effects of stathmin inhibition on the mitotic spindle.

Authors:  C Iancu; S J Mistry; S Arkin; S Wallenstein; G F Atweh
Journal:  J Cell Sci       Date:  2001-03       Impact factor: 5.285

View more
  7 in total

Review 1.  Microtubule targeting agents: from biophysics to proteomics.

Authors:  D Calligaris; P Verdier-Pinard; F Devred; C Villard; D Braguer; Daniel Lafitte
Journal:  Cell Mol Life Sci       Date:  2010-01-28       Impact factor: 9.261

Review 2.  Microtubules and resistance to tubulin-binding agents.

Authors:  Maria Kavallaris
Journal:  Nat Rev Cancer       Date:  2010-02-11       Impact factor: 60.716

3.  Stathmin and interfacial microtubule inhibitors recognize a naturally curved conformation of tubulin dimers.

Authors:  Pascale Barbier; Audrey Dorléans; Francois Devred; Laura Sanz; Diane Allegro; Carlos Alfonso; Marcel Knossow; Vincent Peyrot; Jose M Andreu
Journal:  J Biol Chem       Date:  2010-07-30       Impact factor: 5.157

4.  Stathmin potentiates vinflunine and inhibits Paclitaxel activity.

Authors:  Soazig Malesinski; Philipp O Tsvetkov; Anna Kruczynski; Vincent Peyrot; François Devred
Journal:  PLoS One       Date:  2015-06-01       Impact factor: 3.240

5.  ERG induces taxane resistance in castration-resistant prostate cancer.

Authors:  Giuseppe Galletti; Alexandre Matov; Himisha Beltran; Jacqueline Fontugne; Juan Miguel Mosquera; Cynthia Cheung; Theresa Y MacDonald; Matthew Sung; Sandra O'Toole; James G Kench; Sung Suk Chae; Dragi Kimovski; Scott T Tagawa; David M Nanus; Mark A Rubin; Lisa G Horvath; Paraskevi Giannakakou; David S Rickman
Journal:  Nat Commun       Date:  2014-11-25       Impact factor: 14.919

6.  A PDGFRα-driven mouse model of glioblastoma reveals a stathmin1-mediated mechanism of sensitivity to vinblastine.

Authors:  Hyun Jung Jun; Vicky A Appleman; Hua-Jun Wu; Christopher M Rose; Javier J Pineda; Alan T Yeo; Bethany Delcuze; Charlotte Lee; Aron Gyuris; Haihao Zhu; Steve Woolfenden; Agnieszka Bronisz; Ichiro Nakano; Ennio A Chiocca; Roderick T Bronson; Keith L Ligon; Jann N Sarkaria; Steve P Gygi; Franziska Michor; Timothy J Mitchison; Al Charest
Journal:  Nat Commun       Date:  2018-08-06       Impact factor: 14.919

7.  Stathmin dynamics modulate the activity of eribulin in breast cancer cells.

Authors:  Mikihiro Yoshie; Akari Ishida; Haruka Ohashi; Nami Nakachi; Mana Azumi; Kazuhiro Tamura
Journal:  Pharmacol Res Perspect       Date:  2021-08
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.